The CRC Blueprint

My scientific approach to my own cancer – shared with you.

France

A Study to Evaluate the Adverse Events, and Efficacy of Intravenous (IV) of Telisotuzumab Adizutecan in Combination With IV Oxaliplatin, Fluorouracil, Folinic Acid/Leucovorin, Bevacizumab, Panitumumab in Adult Participants With Metastatic Colorectal Cancer

Phase 2 · randomised · 390 people · 59 sites in 14 countries · Recruiting now

August 7, 2026
Symbiotic-GI-03: A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer

Phase 3 · randomised · 800 people · 285 sites in 17 countries · Recruiting now

August 7, 2026
Study of XL092 + Atezolizumab vs Regorafenib in Participants With Metastatic Colorectal Cancer

Phase 3 · randomised · 901 people · 133 sites in 16 countries · Running, not taking new patients

August 7, 2026
Phase 3 Study of MRTX849 With Cetuximab vs Chemotherapy in Patients With Advanced Colorectal Cancer With KRAS G12C Mutation

Phase 3 · randomised · 461 people · 419 sites in 32 countries · Running, not taking new patients

August 7, 2026
A Study to Evaluate the Safety and Efficacy of Two Dose Levels of ONO-4578 With Opdivo®, in Combination With mFOLFOX6 and Bevacizumab Versus Standard of Care in Participants With Non-MSI-H/dMMR, PD-L1 Positive Advanced Colorectal Cancer

Phase 2 · randomised · 144 people · 39 sites in 6 countries · Recruiting now

August 7, 2026
Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation

Phase 3 · randomised · 450 people · 291 sites in 35 countries · Recruiting now

August 7, 2026
A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer

Phase 3 · randomised · 400 people · 366 sites in 25 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy

Phase 3 · randomised · 700 people · 250 sites in 26 countries · Recruiting now

August 7, 2026
A Study of Amivantamab and mFOLFOX6 or FOLFIRI Versus Cetuximab and mFOLFOX6 or FOLFIRI as First-line Treatment in Participants With KRAS/NRAS and BRAF Wild-type Unresectable or Metastatic Left-sided Colorectal Cancer

Phase 3 · randomised · 1,000 people · 238 sites in 22 countries · Recruiting now

August 7, 2026
A Study to Evaluate the Efficacy and Safety of Standard-of-Care Chemotherapy and Bevacizumab With or Without INCA33890 in the First-Line Treatment of Metastatic Microsatellite Stable Colorectal Cancer

Phase 3 · randomised · 700 people · 254 sites in 21 countries · Recruiting now

August 7, 2026